Spero Therapeutics (NASDAQ:SPRO) Issues Earnings Results, Beats Estimates By $0.01 EPS

Spero Therapeutics (NASDAQ:SPRO) announced its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01, FiscalAI reports. Spero Therapeutics had a return on equity of 35.58% and a net margin of 24.90%.

Here are the key takeaways from Spero Therapeutics’ conference call:

• Utebzi received FDA approval as the first and only oral carbapenem in the U.S. for complicated urinary tract infections, with GSK expecting a U.S. launch in the second half of 2026.
• Spero in-licensed worldwide rights outside Greater China to SP001, a CD40 ligand-targeting antibody for immune-mediated diseases, and plans to begin a Phase II IgG4-related disease trial in the second quarter of 2027.
• The company secured $105 million in non-dilutive, non-recourse royalty financing backed by future Utebzi milestone and royalty payments, extending its expected cash runway into the second half of 2029.
• Second-quarter revenue fell to zero from $14.2 million a year earlier as prior collaboration and government-award funding had been fully recognized; net loss widened to $9.6 million from $1.7 million.

Spero Therapeutics Stock Performance

Shares of NASDAQ SPRO opened at $1.19 on Thursday. Spero Therapeutics has a 52 week low of $1.08 and a 52 week high of $3.08. The stock has a market capitalization of $68.90 million, a PE ratio of 4.96 and a beta of 1.55. The stock has a 50 day moving average price of $1.90 and a 200 day moving average price of $2.29.

Wall Street Analysts Forecast Growth

SPRO has been the subject of several research analyst reports. Wall Street Zen cut shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Spero Therapeutics has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Spero Therapeutics

Several hedge funds have recently bought and sold shares of SPRO. Quadrature Capital Ltd bought a new position in Spero Therapeutics in the 4th quarter valued at approximately $88,000. Millennium Management LLC acquired a new position in Spero Therapeutics during the fourth quarter worth $56,000. Squarepoint Ops LLC bought a new stake in shares of Spero Therapeutics during the 4th quarter valued at $278,000. OMERS ADMINISTRATION Corp purchased a new stake in Spero Therapeutics during the 4th quarter worth about $306,000. Finally, State Street Corp lifted its holdings in Spero Therapeutics by 10.1% during the 4th quarter. State Street Corp now owns 210,151 shares of the company’s stock worth $490,000 after purchasing an additional 19,200 shares in the last quarter. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.